Biopharmaceutical News and Research

RSS

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications.

7 Jan 2020

Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim’s discovery programs.

From PhoreMost 7 Jan 2020

Drug trial seeking treatment option for hyperphagia in patients with Prader-Willi Syndrome

One in every 15,000 children is affected by Prader-Willi syndrome (PWS), a complex, genetic endocrine condition caused by a disorder of chromosome 15. It's non-inheritable, meaning the condition isn't passed down from a family member.

3 Jan 2020

GB Sciences announces preclinical results of promising formulations for Parkinson's disease

GB Sciences, Inc. announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council in Halifax, Nova Scotia, CANADA.

22 Dec 2019

IONTAS antibody for the treatment of B-Cell ALL receives approval for clinical trials

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has been informed that International Biotechnology Center Generium, a leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia.

From FairJourney Biologics 11 Dec 2019

New joint venture aims to develop implantable cell therapies for debilitating conditions with no cure

Mayo Clinic and W. L. Gore & Associates Inc., a global materials science company, have formed a joint venture to advance the development of implantable cell therapies to treat debilitating conditions with no cure. Avobis Bio will combine Mayo Clinic's clinical and cell expertise and Gore's expertise in material sciences to address some of the most challenging medical issues.

10 Dec 2019

Control and Monitor Nanoparticle, Biopharmaceutical and Polymer Product Process

In this interview, Jason Lin, Application Scientist from Wyatt Technology, talks to News-Medical about the new ultraDAWN that is a breakthrough in monitoring nanoparticle biopharmaceutical and polymer product process.

From Waters | Wyatt Technology 10 Dec 2019

US pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceutical industry executives published as part of the recently released CPhI 2019 Annual Report.

From LabVantage Solutions 6 Dec 2019

Pharma’s take on the Pelosi drug-pricing bill: Fair warning or fearmongering?

House Speaker Nancy Pelosi's flagship proposal to curb prescription drug prices, the "Lower Drug Costs Now Act" - H.R. 3 - could come up for a vote in the chamber this month.

5 Dec 2019

Experimental therapies offer patients a greater chance of surviving Ebola virus disease

The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo.

2 Dec 2019

Novoheart collaborates with AstraZeneca to develop world’s first human heart-in-a-jar model of heart failure

Novoheart, a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the world’s first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.

26 Nov 2019

New partnership aims to explore, cultivate innovations in cell and gene therapy

Some patients who have not responded to traditional medicines are now experiencing remarkable recoveries thanks to next-generation immunotherapies. These therapies equip a patient's own immune cells to recognize, target, and destroy cancer cells.

25 Nov 2019

PhoreMost and Sentinel Oncology expand partnership to advance novel allosteric PLK1 inhibitor

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announce an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.

From PhoreMost 15 Nov 2019

Lonza launches new basal and feed medium to optimize protein production

Lonza has further expanded its cell culture media portfolio with the addition of the eCHO Basal Medium and Feed, which has been designed to optimize protein production by delivering a consistent yield and highly viable cells while keeping lactate levels to a minimum for optimal protein integrity.

From Lonza 14 Nov 2019

Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences

Cytel Inc., the leading provider of innovative analytical software and consulting services to the biopharmaceutical sector, and a portfolio company of New Mountain Capital, today announced that it has acquired MTEK Sciences to further expand its advanced real-world analytics capabilities.

From Cytel 8 Nov 2019

Researchers reveal initial results from a study of hypertrophic cardiomyopathy

Researchers have revealed the initial results from the world's largest comprehensive study of hypertrophic cardiomyopathy, an abnormal thickening of the heart that often goes undiagnosed and can prove deadly. The condition can present at any age, and it is the most common cause of sudden cardiac death in young athletes.

7 Nov 2019

Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities

Sphere Fluidics and Peak Analysis and Automation, announce optimization of the Single Cell Analysis System through integration with automated plate handler.

From Fluidic Sciences and Sphere Bio 7 Nov 2019

Panelists explore the issue of drug pricing at ISPOR Europe 2019

ISPOR, the professional society for health economics and outcomes research - explored the issue of drug pricing in the session, "Time for Change? Has the Time Come for the Pharma Industry to Accept Modest Prices?" [IP4].

5 Nov 2019

RCSB Protein Data Bank at Rutgers receives $34.5 million funding

The RCSB Protein Data Bank headquartered at Rutgers University-New Brunswick has been awarded $34.5 million in grants over five years from three U.S. government agencies.

4 Nov 2019

Congressional briefing on moving away from dog studies in the development of new medicines

At a congressional briefing Tuesday, Vanda Pharmaceuticals, the Physicians Committee for Responsible Medicine, and the Humane Society of the United States urged Congress to task the U.S. Food and Drug Administration with moving away from dog studies and other animal testing in the development of new medicines.

30 Oct 2019